News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Eli Lilly and Company Seeks Halt On Generic Strattera Sales
August 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Aug 16 (Reuters) - Eli Lilly and Co (LLY.N) asked a federal judge on Monday to temporarily block sales of generic versions of its Strattera attention deficit disorder drug while it appeals a ruling declaring its patent invalid.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
China
FDA raises bar for foreign site inspections as China trials surge
September 2, 2026
·
4 min read
·
Heather McKenzie
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac
Drug pricing
9 midsize drugmakers climb aboard Trump’s MFN train
September 1, 2026
·
2 min read
·
Tristan Manalac
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
August 31, 2026
·
2 min read
·
Annalee Armstrong
